Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion

PURPOSE: UGT2B17 gene deletion (UGT2B17*2) has been reported to affect bone health as well as the pharmacokinetics of aromatase inhibitor (AI) drugs such as exemestane. The goal of this study was to assess associations between UGT2B17 gene deletion and bone health prior to and after 24 months of AI...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Kamdem, Landry K., Xi, Jingyue, Clark, Brandi L., Gregory, Bryana J., Kidwell, Kelley M., Storniolo, Ana-Maria, Stearns, Vered, Hayes, Daniel F, Gersch, Christina L., Rae, James M., Henry, N. Lynn, Hertz, Daniel L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6534458/
https://ncbi.nlm.nih.gov/pubmed/30747308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-019-05158-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados